Serum Institute Covid-19 vaccine to be made available by end of January 2021: Sharad Pawar

Published On 2020-10-03 08:15 GMT   |   Update On 2020-10-03 08:16 GMT

Pune: Nationalist Congress Party President Sharad Pawar on Friday said that the Covid-19 vaccine being manufactured by the Serum Institute of India (SII) in Pune would be made available by the end of January 2021.

The 79-year-old leader's brief comments came after a visit to the SII facility to get a dose of the BCG vaccine to increase immunity.

Read also: Oxford vaccine clinical trials begin at PGI Chandigarh

This was Pawar's second visit since August to the SII which is currently under global spotlight for its plans to produce vaccines against coronavirus.

SII Chairman Dr Cyrus S. Poonawalla and his son and CEO Adar Poonawala share a close rapport with the Pawar family.

Read also: Serum Institute to develop 200 million doses of COVID vaccine



Tags:    
Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News